Christopher Campen, Principal Medical Science Liaison at Johnson & Johnson Innovative Medicine, shared a post on LinkedIn:
“Could we stop myeloma before it starts?
This is the question driving one of the largest cancer precursor studies in the world and the reason patients, physicians, and supporters will cycle across Iceland this year. The Iceland Cycling Expedition shines a spotlight on one of the most ambitious and impactful research efforts in myeloma: iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma), led by Prof. Sigurdur Kristinsson and supported by the International Myeloma Foundation. Launched in 2017, iStopMM is the first population-wide screening program for precursor conditions MGUS and smoldering multiple myeloma (SMM). Its findings are reshaping how we understand, detect, and manage the disease:
At the end of August, Matthew L. Boyd, Phil Powell, and I will be taking on the challenge of a lifetime by participating in the third annual Iceland Cycling Expedition organized by the International Myeloma Foundation. This ride is a way to raise awareness and funds for multiple myeloma research and patient care.
Our ride is our way of giving back, raising awareness, and showing up for a community that inspires us. If this resonates, I would appreciate your support in advancing this work.
In July, I am setting a very difficult goal of achieving 1000 miles on the bike in support of IMF research – ‘Miles for Myeloma’. If you would like to support us as we fundraise for International Myeloma Foundation – you can donate here.
Together, we can make strides towards a brighter future for patients and families impacted by this disease.
If this resonates, I’d appreciate your support in advancing this work.”
Other articles about Iceland Cycling Expedition on OncoDaily.